Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and...

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...

Alpha Tau Medical Initiates First Clinical Trial in Italy to Treat Cancer with Alpha Radiation TEL AVIV, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical is happy to announce its first clinical trial in Italy. The study at IRST, Meldola, will evaluate the feasibility, safety and...

Alpha Tau Medical avvia la prima sperimentazione clinica in Italia per la cura del tumore con le radiazioni alfa TEL AVIV, Israele, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical è lieta di annunciare l’avvio della sua prima sperimentazione clinica in Italia. Lo studio che sarà condotto presso l’IRST, a...